Linked Life Data

2336876

Source:http://linkedlifedata.com/resource/pubmed/id/2336876

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2336876rdf:typepubmed:Citationlld:pubmed
pubmed-article:2336876lifeskim:mentionsumls-concept:C0042216lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C0206545lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C0008111lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C1514798lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C0025248lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C1171362lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C1515670lld:lifeskim
pubmed-article:2336876lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:2336876pubmed:issue2lld:pubmed
pubmed-article:2336876pubmed:dateCreated1990-6-11lld:pubmed
pubmed-article:2336876pubmed:abstractTextThe immunogenicity and protective efficacy of recombinant vaccinia viruses that express the two major protective antigens of human respiratory syncytial virus (RSV), the F and G glycoproteins, were evaluated in chimpanzees. In previous studies in rodents and monkeys the F and G proteins expressed by the same recombinants were highly immunogenic and induced high levels of resistance to RSV replication following subsequent challenge. In contrast, in chimpanzees, a single intradermal immunization induced only moderate levels of F and G-specific serum antibodies as measured by an enzyme-linked immunosorbent assay, and these antibodies did not efficiently neutralize RSV infectivity in vitro. This poor antibody response in chimpanzees to the F and G glycoproteins occurred despite efficient replication of the vaccinia virus vector as evidenced by lesion size and serum antibody response to vaccinia virus. Upon intranasal RSV challenge, it was observed that prior immunization with the F and G recombinants effected only a marginal reduction in the magnitude and duration of RSV shedding from the nose and trachea and did not reduce illness. However, the RSV challenge induced a strong secondary antibody response, resulting in very high titres (greater than 8000 reciprocal mean titre) of serum neutralizing antibodies. The poor protective efficacy observed here is discussed with regard to the permissiveness of the chimpanzee to RSV replication, the general requirements for effective immunization against RSV, and the limitations of experimental animals for evaluating candidate RSV vaccines.lld:pubmed
pubmed-article:2336876pubmed:languageenglld:pubmed
pubmed-article:2336876pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2336876pubmed:citationSubsetIMlld:pubmed
pubmed-article:2336876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2336876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2336876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2336876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2336876pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2336876pubmed:statusMEDLINElld:pubmed
pubmed-article:2336876pubmed:monthAprlld:pubmed
pubmed-article:2336876pubmed:issn0264-410Xlld:pubmed
pubmed-article:2336876pubmed:authorpubmed-author:LondonW TWTlld:pubmed
pubmed-article:2336876pubmed:authorpubmed-author:ChanockR MRMlld:pubmed
pubmed-article:2336876pubmed:authorpubmed-author:PurcellR HRHlld:pubmed
pubmed-article:2336876pubmed:authorpubmed-author:MurphyB RBRlld:pubmed
pubmed-article:2336876pubmed:authorpubmed-author:CollinsP LPLlld:pubmed
pubmed-article:2336876pubmed:authorpubmed-author:LawrenceL ALAlld:pubmed
pubmed-article:2336876pubmed:issnTypePrintlld:pubmed
pubmed-article:2336876pubmed:volume8lld:pubmed
pubmed-article:2336876pubmed:ownerNLMlld:pubmed
pubmed-article:2336876pubmed:authorsCompleteYlld:pubmed
pubmed-article:2336876pubmed:pagination164-8lld:pubmed
pubmed-article:2336876pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:meshHeadingpubmed-meshheading:2336876-...lld:pubmed
pubmed-article:2336876pubmed:year1990lld:pubmed
pubmed-article:2336876pubmed:articleTitleEvaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.lld:pubmed
pubmed-article:2336876pubmed:affiliationLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.lld:pubmed
pubmed-article:2336876pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2336876lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2336876lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2336876lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2336876lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2336876lld:pubmed